VentriPoint Diagnostics (TSE:VPT) has released an update.
VentriPoint Diagnostics has submitted its innovative VMS+4.0 heart-scanning software for FDA clearance, marking a significant leap in non-invasive cardiac imaging. The new AI-powered technology offers rapid, MRI-quality measurements, enhanced visualization, and ease-of-use features for healthcare providers, promising to revolutionize heart diagnostics from newborns to adults. The company is also seeking regulatory approval in multiple international markets to expand the reach of its advanced cardiac imaging solutions.
For further insights into TSE:VPT stock, check out TipRanks’ Stock Analysis page.
